Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

f long-term obligations1,0881,084  Warrant liability1,9883,422  Long term liabilities4,0884,253  Stockholders' equity60,26566,207Total liabilities and stockholders' equity$
75,354$
82,016Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, May 2, 2013, to provide a business update and discuss the first quarter 2013 results.

A live event will be available on the Investor Relations section of the OncoGenex Web site at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Li
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Boston Scientific Corporation (NYSE: BSX ... purchase the Interventional business of Bayer AG. The ... offer physicians and healthcare systems a more complete ... The addition of the Bayer Interventional ... Boston Scientific strategy to provide a comprehensive portfolio ...
(Date:9/2/2014)... , Sept. 2, 2014  Volcano Corporation ... focused on improving patient and economic outcomes on ... minimally invasive coronary and peripheral visualization, physiology diagnostics ... participating in the Morgan Stanley Healthcare conference on ... Scott Huennekens , president and chief executive ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014  Arena ... that the US Food and Drug Administration (FDA) has ... of pulmonary arterial hypertension. "The FDA ... clinical data submissions from sponsors to identify and designate ... help advance the evaluation and development of such products," ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... successfully enticed one of the best known professionals in emergency medical care ... Dan White , formerly of AllMed , ... subsidiary of Truphatek http://www.truphatek.com/ . ... reached after this week at 573-240-0002 or by e-mail at ...
... 6 Extending its reach into more international high-tech ... has signed Semiconductor Parts and Materials ... components and provide local applications support throughout Europe. Applied ... ultraclean manufacturing of semiconductors, solar cells and pharmaceutical products. ...
Cached Medicine Technology:New Places and People - Truphatek opens USA subsidiary 2New Places and People - Truphatek opens USA subsidiary 3Applied Seals North America Extends Global Network With Addition of Distributor in Europe 2
(Date:9/2/2014)... CITY, GA (PRWEB) September 02, 2014 Last ... whole new level with the launch of a luxurious line ... to announce that the SEA ISLAND COTTON Socks are joining ... compression level, giving more people the comfort of natural cotton ... COTTON Socks, they are surprised to find socks as soft ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 Alliance ... targeting and multi-channel email marketing is pleased to announce ... market, Firearms & Freedom as well as ... properties represent more than one million concerned Americans who ... advertising. , “We are honored to continue providing ...
(Date:9/2/2014)... hospitalized, but your outpatient doctor does not know? ... follow-up care, but your doctor does not have ... Missing or incomplete communication from hospitals to outpatient ... experiences and lead to hospital readmissions. , ... can improve hospitals, communication during patient care transitions. ...
(Date:9/2/2014)... many health risks, including heart disease and diabetes, but ... to mitigate one often-overlooked risk: not buckling up in ... H. Jacobson, a professor of computer science and of ... with a decrease in seatbelt usage. However, these effects ... , "Primary seatbelt laws lead to increased use of ...
(Date:9/2/2014)... Farmington, New York (PRWEB) September 02, 2014 ... Millworks is making it easy to create a consistent look ... the physical structure, to the floor you walk on and ... shop for all custom reclaimed wood designs. , “We’re ... customers to our product line. It saves time, adds consistency, ...
Breaking Medicine News(10 mins):Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2
... The Advertising Standards Authority ruled yesterday that a Walkers ... salt content.// ,According to the industry watchdog ... in its crisps to "7% of your guideline daily ... did not apply to all Walkers crisps. They have ...
... scheme launched in Madhya Pradesh to help malnourished children is ... Shakti scheme was unveiled to aid the 5.7 million malnourished ... years in age, Grassroots Features reported. ,Two-and-a-half-year-old Prem ... 4.2 kg when she was brought to the Bal Shakti ...
... to a new study at the University of Michigan Depression ... not getting// any treatment nor are the ones with the ... ,In the latest issue of General Hospital Psychiatry, the ... of treatment, are not getting enough. ,Without adequate treatment ...
... Bill Gates said inadequate access to treatment and continued discrimination ... in addresses to the largest ever AIDS conference under way ... stigma and stop people from being scared to know their ... Gates have donated billions of dollars to combat the spread ...
... the use of Herceptin in advanced breast cancer patients led ... percent of patients treated with Herceptin// , which no ... of the damage to the heart can be remedied with ... in the Journal of Clinical Oncology, concludes that use of ...
... that reduced levels of testosterone, which is the male sex ... whether a man would die early. ,US scientists ... 858 military veterans aged over 40. Reporting their findings in ... low hormone levels had an 88% increased risk of death ...
Cached Medicine News:Health News:Scheme for Combating Malnourishment in MP Children Yet to Pick Up 2Health News:No therapy for most of the pregnant women with depression 2Health News:No therapy for most of the pregnant women with depression 3Health News:No therapy for most of the pregnant women with depression 4Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 2Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 3Health News:Low Testosterone Linked With Early Death 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: